Graham Scholefield

“Sitting at the boundary between science and business is an incredibly rewarding experience”

COG 150326_Catenion_0233

“I help R&D teams deliver on the promise of gene therapy”

DLI 150326_Catenion_8264

“We help our clients to achieve best practise in managing R&D performance”

Christian Elze

“China’s policy makers are making a concerted long-term effort to build a competitive biomedical innovation system – but R&D-based value creation
is only just beginning.”

Christian Elze Senior Partner
Matthias Krings

“Change-Management is a team effort – let’s get started”

Dr. Matthias Krings Senior Partner
Markus Thunecke

“Is biopharma ready to embrace the new biology?”

Dr. Markus Thunecke Senior Partner
AHN 150326_Catenion_8344

“Translating new technologies into viable business ideas”

Arno Heuermann COO, Partner, Managing Director
Sophie von Dyrander

“My decision to join Catenion? Here I found what I was looking for – high level strategy work, international clients and the team spirit of a smaller firm.”

Spotlight

Biopharma’s Brave New Biology

The Medicine Maker – January 2016 - We live in exciting times for the biopharma industry. The 100-year-old promise of cancer immunotherapy turning cancer into a chronic (if not curable) disease seems within reach in selected indications. …
Download this article

Car-T cell therapy, looking beyond the hype!

While CAR-Ts have already demonstrated convincing efficacy in a specific setting, the jury is still out on whether they are a ‘game-changer’ for oncology as a whole and can justify current valuations and investor interest.
Download

Meet Us

June 3rd - 7th

ASCO Annual Meeting, Chicago, USA

more
May 31st & June 1st

Boston CEO conference, Boston, USA

more
Jan. 30, 2016

The Future of Biopharmaceutical Innovation – The New York Academy of Sciences

more